Legal Medicine
Volume 12, Issue 2 , Pages 57-62 , March 2010

Microglial and astrocytic changes in the striatum of methamphetamine abusers

  • Osamu Kitamura

      Affiliations

    • Department of Legal Medicine, Kanazawa Medical University, Japan
    • Corresponding Author InformationCorresponding author. Address: Department of Legal Medicine, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Kahoku-gun, Ishikawa 920-0293, Japan. Tel.: +81 76 218 8099; fax: +81 76 286 5242.
    • ,
  • Toshiaki Takeichi

      Affiliations

    • Department of Legal Medicine, Kanazawa Medical University, Japan
    • ,
  • Elaine Lu Wang

      Affiliations

    • Department of Legal Medicine, Kanazawa Medical University, Japan
    • ,
  • Itsuo Tokunaga

      Affiliations

    • Department of Forensic Medicine, Institute of Health Bioscience, The University of Tokushima Graduate School, Japan
    • ,
  • Akiko Ishigami

      Affiliations

    • Department of Forensic Medicine, Institute of Health Bioscience, The University of Tokushima Graduate School, Japan
    • ,
  • Shin-ichi Kubo

      Affiliations

    • Department of Forensic Medicine, Fukuoka University School of Medicine, Japan

Received 9 June 2009 ,Revised 19 October 2009 ,Accepted 4 November 2009.

References 

  1. Bowyer JF, Davies DL, Schmued L, Broening HW, Newport GD, Slikker W, et al. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther. 1994;268:1571–1580
  2. O’Callaghan JP, Miller DB. Neurotoxicity profiles of substituted amphetamine in the C57BL/6J mouse. J Pharmacol Exp Ther. 1994;270:741–751
  3. Frey K, Kilbourn M, Robinson T. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur J Pharmacol. 1997;334:273–279
  4. Fukumura M, Cappon GD, Pu C, Broening HW, Vorhees CV. A single dose of methamphetamine-induced neurotoxicity in rats: effects on neostriatal monoamines and glial fibrillary acidic protein. Brain Res. 1998;806:1–7
  5. Cappon GD, Pu C, Vorhees CV. Time-course of methamphetamine-induced neurotoxicity in rat caudate-putamen after single dose treatment. Brain Res. 2000;863:106–111
  6. Johnson-Davis KL, Fleckenstein AE, Wilkins DG. The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity. Eur J Pharmacol. 2003;482:151–154
  7. Segal DS, Kuczenski R, O’Neil ML, Melega WP, Cho AK. Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology. 2003;28:1730–1740
  8. Nakajima A, Yamada K, Nagai T, Uchiyama T, Miyamoto Y, Mamiya T, et al. Role of tumor–necrosis factor-α in methamphetamine-induced drug dependence and neurotoxicity. J Neurosci. 2004;24:2212–2225
  9. De Vito MJ, Wagner GC. Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology. 1989;28:1145–1150
  10. Cadet JL, Brannock C. Free radicals and the pathology of brain dopamine systems. Neurochem Int. 1998;32:117–131
  11. LaVoie MJ, Hastings TG. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci. 1999;19:1484–1491
  12. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography. J Neurosci. 1998;18:8417–8422
  13. Sekine Y, Iyo M, Ouchi Y, Yoshikawa E, Matsunaga T, Tsukada H, et al. Methamphetamine-related symptoms and reduced brain dopamine transporters studies with PET. Am J Psychiatry. 2003;158:1206–1214
  14. Wilson JM, Kalasinski KS, Levey AI, Bergeron C, Reiber G, Anthony RT, et al. Striatal dopamine nerve terminals markers in human, chronic methamphetamine users. Nature Med. 1996;2:699–703
  15. Kitamura O, Tokunaga I, Gotohda T, Kubo S. Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users. Int J Legal Med. 2007;121:163–168
  16. Hanisch HK. Microglia as a source and target of cytokines. Glia. 2002;40:140–155
  17. Streit WJ. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia. 2002;40:133–139
  18. Kim SU, de Vellis J. Microglia in health and disease. J Neurosci Res. 2005;81:302–311
  19. Streit WJ. Microglial cells. In:  Ketterman H,  Ransom BR editor. Neuroglia. 2nd ed.. New York: Oxford University Press; 2005;p. 60–71
  20. Escubedo E, Guitart L, Sureda FX, Jiménez A, Pubill D, Pallàs M, et al. Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats. Brain Res. 1998;814:120–126
  21. Asanuma M, Tsuji T, Miyazaki I, Miyoshi K, Ogawa N. Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketaprofen, a non-steroidal anti-inflammatory drug. Neurosci Lett. 2003;352:13–16
  22. LaVoie MJ, Card JP, Hastings TG. Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp Neurol. 2004;187:47–57
  23. Thomas DM, Dowgiert J, Geddes TJ, Francescutti-Verbeem D, Liu X, Kuhn DM. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci Lett. 2004;367:349–354
  24. Thomas DM, Kuhn DM. Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine. J Neurochem. 2005;92:790–797
  25. Benarroch EE. Neuron-astrocyte interaction: partnership for normal function and disease in the central nervous system. Mayo Clin Proc. 2005;80:1326–1338
  26. Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat. 2002;200:629–638
  27. Nedergaard M, Ransom B, Goldman SA. New roles for astrocytes: redefining the functional architecture of the brain. Trends Neurosci. 2003;26:523–530
  28. Ridet JL, Malhorta SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 1997;23:570–577
  29. O’Callaghan JP. Quantitative features of reactive gliosis following toxicant-induced damage of the CNS. Ann NY Acad Sci. 1993;679:195–210
  30. Pubill D, Canudas AM, Pallás M, Camins A, Camarasa J, Escubedo E. Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn-Schmiedeberg’s Arch Pharmacol. 2003;367:490–499
  31. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358:461–467
  32. Sekine Y, Ouchi Y, Sugihara G, Takei N, Yoshikawa E, Nakamura K, et al. Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci. 2008;28:5756–5761
  33. Mirecki A, Fitzmaurice P, Ang L, Kalasinski KS, Peretti FJ, Aiken SS, et al. Brain antioxidant systems in human methamphetamine users. J Neurochem. 2004;89:1398–1408
  34. Payne J, Maher F, Simpson I, Mattice L, Davies P. Glucose transporter GLUT5 expression in microglial cells. Glia. 1997;21:327–331
  35. Horikoshi Y, Sasaki A, Taguchi N, Maeda M, Tsukagoshi H, Sato K, et al. Human GLUT5 immunolabeling is useful for evaluating microglial status in neuropathological study using paraffin sections. Acta Neuopathol. 2003;105:157–162
  36. Sasaki A, Horikoshi Y, Yokoo H, Nakazato Y, Yamaguchi H. Antiserum against human glucose transporter 5 is highly specific for microglia among cells of the mononuclear phagocyte system. Neurosci Lett. 2003;338:17–20
  37. Gräber MB, Bise K, Mehraein P. CR3/43, a marker for activated human microglia: application to diagnostic neuropathology. Neuropathol Appl Neurobiol. 1994;20:406–408
  38. Rothermundt M, Peters M, Prehn JHM, Arolt V. S100B in brain damage and neurodegeneration. Microsc Res Tech. 2003;60:614–632
  39. Li DR, Zhu BL, Ishikawa T, Zhao D, Michiue T, Maeda H. Immunohistochemical distribution of S-100 protein in the cerebral cortex with regard to the cause of death in forensic autopsy. Legal Med. 2006;8:78–85
  40. Steiner J, Bernstein H-G, Bielau H, Berndt A, Brisch R, Mawrin C, et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BCM Neurosci. 2007;8:2
  41. Ishigami A, Tokunaga I, Gotohda T, Kubo S. Immunohistochemical study of myoglobin and oxidative injury-related markers in the kidney of methamphetamine abusers. Legal Med. 2003;5:42–48
  42. Stadlin A, Lau JWS, Szeto YK. A selective regional response of cultured astrocytes to methamphetamine. Ann NY Acad Sci. 1998;844:108–121
  43. Oehmichen M, Meißner C, Reiter A, Birkholz M. Neuropathology in non-human immunodeficiency virus-infected drug addicts: hypoxic brain damage after chronic intravenous drug abuse. Acta Neuropathol. 1996;91:642–646
  44. Büttner A, Weis S. Neuropathological alterations in drug abusers – the involvement of neurons, glial and vascular systems. Forensic Sci Med Pathol. 2006;2:115–126
  45. In SW, Son EW, Rhee DK, Pyo S. Methamphetamine administration produces immunomodulation in mice. J Toxicol Environ Health A. 2005;68:2133–2145
  46. Langford D, Adame A, Grigorian A, Grant I, MacCutchan J, Ellis RJ, et al. Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr. 2003;34:467–474

PII: S1344-6223(09)00360-5

doi: 10.1016/j.legalmed.2009.11.001

Legal Medicine
Volume 12, Issue 2 , Pages 57-62 , March 2010

Article Tools

* Image Usage & Resolution